Abstract

The cyclic five-membered disulfide 1,2-dithiolane has been widely used in chemical biology and in redox probes. Contradictory reports have described it either as nonspecifically reduced in cells, or else as a highly specific substrate for thioredoxin reductase (TrxR). Here we show that 1,2-dithiolane probes, such as “TRFS” probes, are nonspecifically reduced by thiol reductants and redox-active proteins, and their cellular performance is barely affected by TrxR inhibition or knockout. Therefore, results of cellular imaging or inhibitor screening using 1,2-dithiolanes should not be interpreted as reflecting TrxR activity, and previous studies may need re-evaluation. To understand 1,2-dithiolanes’ complex behaviour, probe localisation, environment-dependent fluorescence, reduction-independent ring-opening polymerisation, and thiol-dependent cellular uptake must all be considered; particular caution is needed when co-applying thiophilic inhibitors. We present a general approach controlling against assay misinterpretation with reducible probes, to ensure future TrxR-targeted designs are robustly evaluated for selectivity, and to better orient future research.

Cyclic five-membered disulfides (1,2-dithiolanes) have been reported either as nonspecific redox motifs, or as highly specific cellular probes for thioredoxin reductase (TrxR). Here the authors show that 1,2-dithiolane probes are nonspecifically reduced by a range of thiol reductants and are not sensitive to TrxR modulation, thus they are unsuitable as cellular probes for TrxR.

Details

Title
Cyclic 5-membered disulfides are not selective substrates of thioredoxin reductase, but are opened nonspecifically
Author
Felber, Jan G 1   VIAFID ORCID Logo  ; Poczka Lena 1 ; Scholzen, Karoline C 2   VIAFID ORCID Logo  ; Zeisel Lukas 1   VIAFID ORCID Logo  ; Maier, Martin S 1 ; Sander, Busker 3 ; Theisen Ulrike 4   VIAFID ORCID Logo  ; Brandstädter Christina 5 ; Becker, Katja 5 ; Arnér Elias S J 6   VIAFID ORCID Logo  ; Thorn-Seshold Julia 1   VIAFID ORCID Logo  ; Thorn-Seshold Oliver 1   VIAFID ORCID Logo 

 Ludwig-Maximilians University Munich, Department of Pharmacy, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X) 
 Karolinska Institutet, Department of Medical Biochemistry, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
 Karolinska Institutet, Department of Medical Biochemistry, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Pelago Bioscience AB, Solna, Sweden (GRID:grid.502683.a) 
 Cellular and Molecular Neurobiology, TU Braunschweig, Zoological Institute, Braunschweig, Germany (GRID:grid.6738.a) (ISNI:0000 0001 1090 0254) 
 Justus-Liebig University Giessen, Interdisciplinary Research Centre (IFZ), Giessen, Germany (GRID:grid.8664.c) (ISNI:0000 0001 2165 8627) 
 Karolinska Institutet, Department of Medical Biochemistry, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); National Institute of Oncology, Department of Selenoprotein Research, Budapest, Hungary (GRID:grid.419617.c) (ISNI:0000 0001 0667 8064) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2646021247
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.